Montreal, July 21, 2020 – The Canadian Hemophilia Society has in recent days made submissions to both CADTH (Canadian Agency for Drugs and Technologies in Health) and INESSS (Institut national d’excellence en santé et en services sociaux) to present the patient perspectives in the context of the possible introduction of Hemlibra (emicizumab) for the treatment of hemophilia A without inhibitors. The two agencies are expected to take up to six months to complete their evaluations and make recommendations, INESSS to the Quebec government, and CADTH to the other provinces and territories, on whether or not to list this therapy on the Héma-Québec and Canadian Blood Services drug formularies. While the CHS will be advocating for early and positive decisions, patient access is not anticipated until 2021.
The CHS would like to thank all those who contributed to the preparation of the submissions, including those individuals who provided their perspectives via participation in CHS online surveys or by offering personal testimonials.
CLICK HERE to access the submission to CADTH
Click here to access the submission to INESSS (in French)
